Autori: Portoles Jose
| Naslov | Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies (Article) |
| Autori | Barratt Jonathan Dellanna Frank Portoles Jose Choukroun Gabriel De Nicola Luca Young James Dimkovic Nada B Reusch Michael |
| Info | ADVANCES IN THERAPY, (2023), vol. 40 br. 4, str. 1546-1559 |
| Projekat | Astellas Pharma, Inc.; Astellas Pharma, Inc. [DOLOMITES: NCT02021318]; FibroGen, Inc. [SIERRAS: NCT02273726, HIMALAYAS: NCT02052310]; AstraZeneca [ROCKIES: NCT02174731] |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies (Article) |
| Autori | Barratt Jonathan Dellanna Frank Portoles Jose Choukroun Gabriel De Nicola Luca Young James Dimkovic Nada B Reusch Michael |
| Info | ADVANCES IN THERAPY, (2023), vol. 40 br. 4, str. 1546-1559 |
| Projekat | Astellas Pharma, Inc. (DOLOMITES); FibroGen, Inc.; AstraZeneca; [NCT02021318]; [NCT02273726]; [NCT02052310]; [NCT02174731] |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: |
